SCHEMBL16320778

SCHEMBL16320778

Cc1ncc(C)c(-c2cn(C)nc2C)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.41
COMT P21964 1/20 0.39
CCNB2 O95067 1/20 0.36
CCNE2 O96020 1/20 0.36
CDK1 P06493 1/20 0.36
CCNB1 P14635 1/20 0.36
CCNE1 P24864 1/20 0.36
CDK2 P24941 1/20 0.36
CDK5 Q00535 1/20 0.36
CDK5R1 Q15078 1/20 0.36
CCNB3 Q8WWL7 1/20 0.36
PIK3CA P42336 3/20 0.36
PIK3CG P48736 3/20 0.36
S1PR2 O95136 4/20 0.34
BRD4 O60885 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.33
PIK3CD O00329 3/20 0.33
PIK3CB P42338 2/20 0.33
MTOR P42345 2/20 0.33
PIK3C3 Q8NEB9 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16320539 0.83 ALDH1A1 (0.40) ALDH1A1COMTCCNB2CCNE2CDK1
SCHEMBL16320365 0.83 CCNB2 (0.50) ALDH1A1COMTCCNB2CCNE2CDK1
SCHEMBL18916807 0.77 ADORA2A (0.43) CDK2S1PR2
SCHEMBL16320095 0.76 COMT (0.39) ALDH1A1COMTCCNB2CCNE2CDK1
SCHEMBL16321045 0.75 ALDH1A1 (0.44) ALDH1A1COMTCCNB2CCNE2CDK1
SCHEMBL16341708 0.74 ALDH1A1 (0.42) ALDH1A1COMTCCNB2CCNE2CDK1
SCHEMBL17059345 0.71 CCNB2 (0.51) ALDH1A1COMTCCNB2CCNE2CDK1
SCHEMBL16561354 0.71 COMT (0.47) ALDH1A1COMTCCNB2CCNE2CDK1
SCHEMBL16561261 0.70 JAK2 (0.44) CDK2
SCHEMBL25613555 0.69 TTK (0.42) ALDH1A1COMTCDK2BRD4HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9777000-B2 Pyrazole derivative MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2017-10-03 US disclosed
US-20160347751-A1 NOVEL PYRAZOLE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2016-12-01 US disclosed
US-9458157-B2 Pyrazole derivative MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2016-10-04 US disclosed
US-9440970-B2 Pyrazole derivative MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2016-09-13 US disclosed
US-20150133448-A1 NOVEL PYRAZOLE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2015-05-14 US disclosed
US-20150132327-A1 NOVEL PYRAZOLE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2015-05-14 US disclosed
US-8980889-B2 Pyrazole derivative MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2015-03-17 US disclosed
US-8980888-B2 Pyrazole derivative MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2015-03-17 US disclosed
US-20140378447-A1 NOVEL PYRAZOLE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2014-12-25 US disclosed
US-20140378448-A1 NOVEL PYRAZOLE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2014-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140378447-A1 NOVEL PYRAZOLE DERIVATIVE PDE10A, PDE3A, PDE5A ALDH1A1 387/4885COMT 447/4885CCNB2 4210/4885
US-20160347751-A1 NOVEL PYRAZOLE DERIVATIVE PDE10A, PDE3A, PDE5A ALDH1A1 387/4885COMT 447/4885CCNB2 4210/4885
US-20140378448-A1 NOVEL PYRAZOLE DERIVATIVE PDE10A, PDE3A, PDE5A ALDH1A1 387/4885COMT 447/4885CCNB2 4210/4885
US-20150133448-A1 NOVEL PYRAZOLE DERIVATIVE PDE10A, PDE3A, PDE5A ALDH1A1 387/4885COMT 447/4885CCNB2 4210/4885
US-20150132327-A1 NOVEL PYRAZOLE DERIVATIVE PDE10A, PDE3A, PDE5A ALDH1A1 387/4885COMT 447/4885CCNB2 4210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.